MEDI LIFESTYLE LIMITED
AND ITS SUBSIDIARIES

Company Registration No: 201117734D

CONDENSED INTERIM FINANCIAL STATEMENTS

FOR THE THIRD QUARTER ("3Q2026") AND NINE MONTHS ("9M2026'')

ENDED 30 SEPTEMBER 2026

In view of the material uncertainty related to going concern assumption issued by the Company's independent auditors, CLA Global TS Public Accounting Corporation on the audited financial statements of the Group for the financial year ended 31 December 2025, the Company is required by the Singapore Exchange Securities Trading Limited ("Exchange") to announce its quarterly financial statements pursuant to Catalist Rule 705.

Contents

		Page
A.	Condensed interim consolidated statement of profit or loss and other comprehensive income	2
B.	Condensed interim statements of financial position	3
C.	Condensed interim statements of changes in equity	4
D.	Condensed interim consolidated statement of cash flows	5
E.	Selected notes to the condensed interim consolidated financial statements	6
F.	Other information required by Catalist Rule Appendix 7C	19

A. CONDENSED INTERIM CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

Group	Note	3 months ended 30 September ("3Q")			9 months ended 30 September ("9M")		
		3Q2026 RM'000 (Unaudited)	3Q2025 RM'000 (Unaudited)	Change +/(-) %	9M2026 RM'000 (Unaudited)	9M2025 RM'000 (Unaudited)	Change +/(-) %
Continuing operations[(a)]							
Revenue	4	168	103	63.1	471	4,124	(88.6)
Cost of sales		(156)	(162)	(3.7)	(458)	(4,205)	(89.1)
Gross profit/(loss)		12	(59)	n.m.	13	(81)	n.m.
Other operating income		-	-	-	29	7	>100.0
Administrative expenses		(1,518)	(845)	79.6	(3,206)	(2,245)	42.8
Exchange loss		(172)	(6)	>100.0	(139)	(55)	>100.0
Other operating expenses		(63)	-	n.m.	(63)	(4)	n.m.
Finance costs		(3)	(25)	(88.0)	(49)	(80)	(38.8)
Loss before tax	5	(1,744)	(935)	86.5	(3,415)	(2,458)	38.9
Income tax		-	-	-	-	-	-
Loss for the period from continuing operations		(1,744)	(935)	86.5	(3,415)	(2,458)	38.9
Discontinued operations[(b)]	6						
Loss for the period from discontinued operations		-	(127)	n.m.	(360)	(361)	(0.3)
Net loss for the year		(1,744)	(1,062)	64.2	(3,775)	(2,819)	33.9
Other comprehensive loss, net of tax							
- Exchange differences on translation of foreign operations		298	36	>100.0	246	(28)	n.m.
Total comprehensive loss for the period, net of tax		(1,446)	(1,026)	40.9	(3,529)	(2,847)	24.0
Total loss attributable to:							
Owners of the Company							
- Continuing operations		(1,744)	(935)	86.5	(3,415)	(2,458)	38.9
- Discontinued operations		-	(127)	n.m.	(360)	(361)	(0.3)
Non-controlling interests		-	-	-	-	-	-
		(1,744)	(1,062)	64.2	(3,775)	(2,819)	33.9
Total comprehensive loss attributable to:							
- Owners of the Company		(1,446)	(1,026)	40.9	(3,529)	(2,847)	24.0
- Non-controlling interests		-	-	-	-	-	-
		(1,446)	(1,026)	40.9	(3,529)	(2,847)	24.0
Loss per share for the period attributable to owners of the Company							
Basic and diluted (Malaysia sen)							
- From continuing operations		(0.28)	(0.57)		(0.66)	(1.50)	
- From discontinued operations		-	(0.08)		(0.07)	(0.22)	

n.m. denotes not meaningful

Notes:

(a) The financial results presented under continuing operations for 3Q2026 and 9M2026 comprises of the commodity trading sector, outsourced services sector and corporate.

(b) Financial statements for 3Q2026, 3Q2025, 9M2026 and 9M2025 have been presented after reclassifying the subsidiaries under the Healthcare sector under discontinued operations.

B. CONDENSED INTERIM STATEMENTS OF FINANCIAL POSITION

	Note	Company		Group	
		As at 30 September 2026 RM'000 (Unaudited)	As at 31 December 2025 RM'000 (Audited)	As at 30 September 2026 RM'000 (Unaudited)	As at 31 December 2025 RM'000 (Audited)
Current assets					
Cash and bank balances		30,387	156	30,412	261
Trade receivables	7	-	-	92	161
Other receivables and prepayments	8	1,228	42	322	247
Inventories		-	-	-	124
		31,615	198	30,826	793
Non-current asset					
Plant and equipment	9	-	-	-	53
Investments in subsidiaries	10	-	-	-	-
		-	-	-	53
Total assets		**31,615**	**198**	**30,826**	**846**
Current liabilities					
Other payables	11	542	1,065	819	1,573
Provisions	12	-	-	52	57
Borrowings	13	296	1,197	296	1,197
Contract liabilities		-	-	-	61
Amounts due to shareholders	14	-	3,433	-	3,433
Income tax payable		-	-	-	4
		838	5,695	1,167	6,325
Total liabilities		**838**	**5,695**	**1,167**	**6,325**
Capital and reserves					
Share capital		186,047	147,380	186,047	147,380
Treasury shares		(38)	(38)	(38)	(38)
Currency translation reserve		1,147	1,002	190	(56)
Capital reserve		3,893	3,893	3,893	3,893
Accumulated losses		(160,272)	(157,734)	(160,433)	(156,658)
Equity attributable to owners of the Company		30,777	(5,497)	29,659	(5,479)
Non-controlling interests		-	-	-	-
Net equity / (capital deficiency)		**30,777**	**(5,497)**	**29,659**	**(5,479)**
Total liabilities and equity		**31,615**	**198**	**30,826**	**846**

C. CONDENSED INTERIM STATEMENTS OF CHANGES IN EQUITY

Company

	Share capital (RM'000)	Treasury shares (RM'000)	Accumulated losses (RM'000)	Capital reserve (RM'000)	Currency translation reserve (RM'000)	Total (RM'000)
At 1 January 2026	147,380	(38)	(157,734)	3,893	1,002	(5,497)
Total comprehensive income / (loss) for the period	-	-	(2,538)	-	145	(2,393)
Transaction with owners:						
Increase in paid-up capital	39,763	-	-	-	-	39,763
Capitalised expenses	(1,096)	-	-	-	-	(1,096)
At 30 September 2026	**186,047**	**(38)**	**(160,272)**	**3,893**	**1,147**	**30,777**

Company

	Share capital (RM'000)	Treasury shares (RM'000)	Accumulated losses (RM'000)	Capital reserve (RM'000)	Currency translation reserve (RM'000)	Total (RM'000)
At 1 January 2025	136,574	(38)	(153,422)	14,420	794	(1,672)
Total comprehensive income / (loss) for the period	-	-	(1,430)	-	21	(1,409)
Transaction with owners:						
Increase in paid-up capital	330	-	-	-	-	330
Capitalised expenses	(26)	-	-	-	-	(26)
At 30 September 2025	**136,878**	**(38)**	**(154,852)**	**14,420**	**815**	**(2,777)**

Group

	Share capital (RM'000)	Treasury shares (RM'000)	Accumulated losses (RM'000)	Capital reserve (RM'000)	Currency translation reserve (RM'000)	Equity attributable to owners of the Company (RM'000)	Non-controlling interests (RM'000)	Total equity (RM'000)
At 1 January 2026	147,380	(38)	(156,658)	3,893	(56)	(5,479)	-	(5,479)
Loss for the year	-	-	(3,775)	-	-	(3,775)	-	(3,775)
Other comprehensive income								
- Currency translation difference arising from consolidation	-	-	-	-	246	246	-	246
Transaction with owners:								
Increase in paid-up capital	39,763	-	-	-	-	39,763	-	39,763
Capitalised expenses	(1,096)	-	-	-	-	(1,096)	-	(1,096)
At 30 September 2026	**186,047**	**(38)**	**(160,433)**	**3,893**	**190**	**29,659**	**-**	**29,659**

Group

	Share capital (RM'000)	Treasury shares (RM'000)	Accumulated losses (RM'000)	Capital reserve (RM'000)	Currency translation reserve (RM'000)	Equity attributable to owners of the Company (RM'000)	Non-controlling interests (RM'000)	Total equity (RM'000)
At 1 January 2025	136,574	(38)	(152,800)	14,420	253	(1,591)	-	(1,591)
Loss for the year	-	-	(2,819)	-	-	(2,819)	-	(2,819)
Other comprehensive loss								
- Exchange difference on translating foreign operations	-	-	-	-	(28)	(28)	-	(28)
Transaction with owners:								
Increase in paid-up capital	330	-	-	-	-	330	-	330
Capitalised expenses	(26)	-	-	-	-	(26)	-	(26)
At 30 September 2025	**136,878**	**(38)**	**(155,619)**	**14,420**	**225**	**(4,134)**	**-**	**(4,134)**

D. CONDENSED INTERIM CONSOLIDATED STATEMENT OF CASH FLOWS

Group	3 Months ended 30 September ("3Q")		9 Months ended 30 September ("9M")	
	3Q2026 RM'000 (Unaudited)	3Q2025 RM'000 (Unaudited)	9M2026 RM'000 (Unaudited)	9M2025 RM'000 (Unaudited)
CASH FLOWS FROM OPERATING ACTIVITIES				
Loss before tax				
- Continuing operations	(1,744)	(935)	(3,415)	(2,458)
- Discontinued operations	-	(127)	(360)	(361)
	(1,744)	(1,062)	(3,775)	(2,819)
Adjustments for:				
Depreciation of property, plant and equipment	-	11	20	34
Loss arising from extinguishment of loan	63	-	63	-
Loss on discontinued healthcare business	-	-	125	-
Loss in fair value of hybrid financial instruments	-	-	-	4
Interest expenses	3	25	49	80
Operating loss before working capital changes	(1,678)	(1,026)	(3,518)	(2,701)
Inventories	-	1	9	11
Trade and other receivables and prepayments	(35)	678	(2)	176
Contract liabilities	-	2	(38)	1
Trade and other payables and other provisions	(2,000)	(469)	(939)	(656)
Tax paid	-	-	(4)	(14)
Net cash used in operating activities	(3,713)	(814)	(4,492)	(3,183)
CASH FLOWS FROM INVESTING ACTIVITIES				
Purchase of plant and equipment	-	(4)	-	(4)
Net cash used in investing activities	-	(4)	-	(4)
CASH FLOWS FROM FINANCING ACTIVITIES				
Repayment of loans and interest	(1,017)	-	(1,017)	(74)
(Repayment of) / proceeds from loans /advances from shareholders	(5,195)	-	-	2,709
Repayment of loans to shareholder	(1,985)	-	(1,985)	-
Proceeds from issuance of ordinary shares	38,206	-	38,206	-
Capitalised transaction costs on issuance of ordinary shares	(1,096)	-	(1,096)	(26)
Net cash generated from financing activities	28,913	-	34,108	2,609
Net increase / (decrease) in cash and cash equivalents	25,200	(818)	29,616	(578)
Cash and cash equivalents at beginning of the period	4,726	1,316	261	1,067
Currency translation difference of cash and cash equivalents at beginning of the period	486	(7)	535	2
Cash and cash equivalents at end of period	30,412	491	30,412	491

E. SELECTED NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

1. Corporate and group information

Medi Lifestyle Limited (the "**Company**") (Registration No. 201117734D) is incorporated in Singapore with its registered office at 380 Jalan Besar, #07-10 ARC 380, Singapore 209000. Its shares are publicly traded on the Catalist board of the Singapore Exchange.

The principal activity of the Company is that of investment holding. The principal activities of its subsidiaries are in the Outsourced Services and Commodity Trading.

Following a strategic review conducted during the six months ended 30 June 2026 as part of the Group's efforts to streamline its operations and divest or cease its non-performing businesses, the Group discontinued the operations of both Back to Life Sdn Bhd and Healthpro Marketing Sdn Bhd (collectively, the "**Healthcare Services**"), which remained classified as discontinued operations as at 30 September 2026.

Accordingly, the comparative statement of profit or loss and other comprehensive income for the three months ("**3Q2026**") and nine months ended 30 September 2026 ("**9M2026**") has been represented to separately disclose the discontinued operations from continuing operations in accordance with the requirements of SFRS(I) 5 Non-current Assets Held for Sale and Discontinued Operations.

The financial results for continuing operations presented for 3Q2026 and 9M2026 comprise of (i) Outsourced Services in Singapore currently focused on human resource recruitment; and (ii) Commodity Trading sector.

2. Basis of preparation

The condensed interim financial statements for 3Q2026 and 9M2026 have been prepared in accordance with SFRS(I) 1-34 Interim Financial Reporting issued by the Accounting Standards Council Singapore. The condensed interim financial statements do not include all the information required for a complete set of financial statements. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group's financial position and performance of the Group since the last audited financial statements for the twelve months ended 31 December 2025.

The interim statements of financial position of the Company and its subsidiaries as at 30 September 2026 and related interim consolidated statement of profit or loss and other comprehensive income, interim consolidated statement of changes in equity and interim consolidated statement of cash flows for 3Q2026 and 9M2026 and certain explanatory notes have not been independently audited or reviewed by external auditor.

Except as disclosed in Note 2.1 below, the Group has applied the same accounting policies and methods of computation in the financial statements for current financial period reported on, as those applied in the Group's most recently audited financial statements for the financial year ended 31 December 2025, which were prepared in accordance with Singapore Financial Reporting Standards (International) ("**SFRS(I)s**").

The individual financial statements of each Group entity are measured and presented in the currency of the primary economic environment in which the entity operates its functional currency. The functional currency of the Company is Singapore Dollar ("**S$**") while the consolidated financial statements of the Group and the statement of financial position and statement of changes in equity of the Company are presented in Malaysia Ringgit ("**RM**"). All values are rounded to the nearest thousand ("**RM'000**") except when otherwise indicated.

2.1 New and amended standards adopted by the Group

The Group has adopted all the new and revised SFRS(I) and SFRS(I) Interpretations ("**SFRS(I) INTs**") that are relevant to its operations and effective for annual periods beginning on or after 1 January 2026, where applicable. The adoption of these standards from the effective date has not resulted in material adjustments to the financial position, results of operations or cash flows of the Group for 3Q2026 and 9M2026. The Group did not have to change its accounting policies or make retrospective adjustments as a result of adopting those standards.

2.2 Use of estimates and judgement

In preparing the condensed interim financial statements, management has made judgements, estimates and assumptions about the carrying amount of assets and liabilities that were not readily apparent from other sources in the application of the Group's accounting policies. Estimates and judgements are continually evaluated and are based on historical experience and other factors considered to be reasonable under the circumstances. Actual results may differ from these estimates. Other than the following disclosure, there are no critical judgement made by management in the process of applying the Group's accounting policies which may have the most significant effect on the amounts recognised in the financial statements.

Going concern assumption

The preparation of the financial statements on a going concern basis requires management to exercise significant judgement in assessing the Group's and the Company's ability to continue as going concerns for a period of at least 12 months from the end of the reporting period. This includes consideration of the Group's financial position, liquidity requirements and the availability of financial support from its controlling shareholder.

Such assessment involves judgement over the controlling shareholder's intention and ability to provide financial support as and when required and not to demand repayment of amounts owing within the assessment period, which are subject to inherent uncertainties.

Further details of the assumptions and conditions relating to the going concern assessment are disclosed in Note 2.3 to the financial statements below.

Impairment of investment in subsidiaries

Management exercises significant judgement in assessing whether there are indicators of impairment and estimating the recoverable amounts of the Company's investments in subsidiaries.

Where impairment indicators are identified, the recoverable amounts is determined based on the higher of fair value less costs of disposal and value-in-use. In assessing value-in-use, management is required to make assumptions on future cash flows, including revenue growths, margins and timing of cash flows, as well as determining an appropriate discount rate.

These assumptions are inherently uncertain and are affected by future market and economic conditions. Changes in these assumptions may result in material adjustments to the carrying amounts of the investments.

Net realisable value of inventory

Inventories, comprising exosome hair serum, exosome face serum, orthotic products and consumables are stated at the lower of cost and net realisable value. Management exercises judgement in assessing the net realisable value of inventories, taking into consideration recent selling prices, current market conditions and the expected saleability of the products.

Management reviews inventory ageing and sales trends to identify slow-moving or obsolete items. In particular, due to the nature of skincare products, factors such as changes in consumer preferences, product shelf life and pricing competition may affect the recoverability of inventories. Where necessary, an allowance is made to write-down inventories to their net realisable value. These assessments involve inherent uncertainties, and changes in market demand or pricing may result in material adjustments to the carrying amounts of inventories.

Impairment review of plant and equipment

Plant and equipment are reviewed for impairment whenever there is any indication that the assets are impaired. If any such indication exists, the recoverable amount (i.e. higher of the fair value less costs of disposal and value-in-use) of the asset is estimated to determine the impairment loss.

The recoverable amount is determined based on the fair value less costs of disposal ("**FVLCD**") method by reference to market quotations which involves significant management estimation and relies on assumptions that are influenced by future market and economic conditions. Where the carrying amount of plant and equipment exceeds the recoverable amount determined using FVLCD, an impairment loss is recognised in profit or loss.

Loss allowance for trade receivables
The Group uses a provision matrix to measure expected credit loss ("**ECL**") for trade receivables. Management exercises judgement in determining the appropriate ECL rates, which are based on historical loss experience over the past 3 years, adjusted for forward-looking information.

The provision matrix is developed by grouping customers based on shared credit risk characteristics, including geographical location, product types and internal credit ratings. Forward-looking adjustments are made to reflect current and expected economic conditions, including factors such as gross domestic product growth rates and industry trends in the markets in which the Group operates.

These estimates involve significant judgement and uncertainty, and actual credit losses may differ from those estimated. Changes in economic conditions or customer credit profiles may result in material adjustments to the loss allowance.

Further details of the assumptions applied are disclosed in Note 7 to the financial statements below.

Fair value of convertible loans
Management exercises significant judgement in determining the appropriate classification of convertible loan notes as either compound financial instruments or hybrid financial instruments.

This assessment requires evaluation of the contractual terms of the instruments, including whether the conversion feature meets the "fixed-for-fixed" criterion, i.e. whether the convertible loan can be settled by issuing a fixed number of shares in exchange for a fixed amount of cash. Where the criterion is not met, the instruments are classified as hybrid financial instruments and measured at fair value through profit or loss.

During the financial year ended 31 December 2025, the convertible loan notes were fully converted into equity shares of the Company in accordance with the contractual terms.

2.3 Going concern assumption

As at 30 September 2026, the Group had net assets and net current assets of RM29.7 million. The Company had net assets and net current assets of RM30.8 million. The Group incurred a net loss of RM3.8 million and recorded net operating cash outflows of RM4.5 million for the nine months ended 30 September 2026.

To support the financial statements having been prepared on a going concern basis and to ensure the adequacy of funds required to meet its obligations, working capital and capital commitment needs, the Group prepared a 12-month consolidated cash flow forecast from 1 October 2026 ("**Cash Flow Forecast**"). In preparing the Cash Flow Forecast, the management has taken into consideration (i) the net proceeds of S$3.6 million received upon the completion of the Company's renounceable non-underwritten rights issue of 189,051,006 new ordinary shares of the Company at issue price of S$0.02 per Rights Share on 6 July 2026, on the basis of one (1) Rights Share for every two (2) existing Shares of the Company held as at the record date (the "**Rights Issue**"), and (ii) the net proceeds of S$8.6 million received upon the completion of the Company's placement of 178,588,000 new ordinary shares of the Company at issue price of S$0.049 per Placement Share on 25 August 2026.

2.4 Board's comments on going concern assumption

In the assessment of the Group's and the Company's going concern, the Board has considered the Cash Flow Forecast prepared by management, including estimated earnings from the Group's business activities and the receipt of the net proceeds of S$3.6 million and S$8.6 million upon the completion of the Rights Issue and Shares Placement on 6 July 2026 and 25 August 2026 respectively. The funds raised has strengthened the Group's and Company's liquidity and capital positions.

Barring any unforeseen circumstances and any adverse impact from a global economic slowdown, the Board is of the opinion that the Group and the Company are able to meet their working capital commitments for the next 12 months and the Group's and the Company's financial statements be prepared on a going concern basis.

3. Seasonal operations

The Group's businesses are not affected significantly by seasonal or cyclical factors during the financial period.

4. Segmental and revenue information

The Group's reportable segments were identified as follows:

Continuing Operations consist of:

- Corporate – investment holding activities
- Outsourced Services – human resource recruitment
- Commodity Trading – agricultural commodities trading in the Asia-Pacific region

Discontinued Operations consist of:

- Healthcare Services – chiropractic & physiotherapy services.

These operating segments are reported in a manner consistent with internal reporting provided to the Chief Executive Officer who is responsible for allocating resources and assessing performance of the operating segments.

4. Segmental and revenue information (cont'd)

4.1 Reportable segments

The segment analysis on the Group's results for three months ended 30 September 2026 ("**3Q2026**") and 30 September 2025 ("**3Q2025**") are as follows:

Group	Continuing Operations						Discontinued Operations		Combined	
	Outsourced Services		Commodity Trading		Corporate		Healthcare			
	3Q2026 RM'000	3Q2025 RM'000	3Q2026 RM'000	3Q2025 RM'000	3Q2026 RM'000	3Q2025 RM'000	3Q2026 RM'000	3Q2025 RM'000	3Q2026 RM'000	3Q2025 RM'000
REVENUE										
Total sales	168	103	-	-	-	-	-	19	168	122
Inter-segment sales	-	-	-	-	-	-	-	(1)	-	(1)
External sales	168	103	-	-	-	-	-	18	168	121
RESULTS										
Segment results	(9)	(90)	(7)	(17)	(1,725)	(803)	-	(127)	(1,741)	(1,037)
Finance costs	-	-	-	-	(3)	(25)	-	-	(3)	(25)
	(9)	(90)	(7)	(17)	(1,728)	(828)	-	(127)	(1,744)	(1,062)
Taxation									-	-
Loss for the period									(1,744)	(1,062)
Loss attributable to										
- owners of the Company									(1,744)	(1,062)
- non-controlling interest									-	-
Loss for the period									(1,744)	(1,062)
Depreciation of plant and equipment	-	-	-	-	-	(3)	-	(8)	-	(11)
Loss arising from extinguishment of loan	-	-	-	-	(63)	-	-	-	(63)	-

4. Segmental and revenue information (cont'd)

4.1 Reportable segments (cont'd)

The segment analysis on the Group's results for nine months ended 30 September 2026 ("**9M2026**") and 30 September 2025 ("**9M2025**") are as follows:

Group	Continuing Operations						Discontinued Operations		Combined	
	Outsourced Services		Commodity Trading		Corporate		Healthcare			
	9M2026 RM'000	9M2025 RM'000	9M2026 RM'000	9M2025 RM'000	9M2026 RM'000	9M2025 RM'000	9M2026 RM'000	9M2025 RM'000	9M2026 RM'000	9M2025 RM'000
REVENUE										
Total sales	471	354	-	3,770	-	-	115	78	586	4,202
Inter-segment sales	-	-	-	-	-	-	-	(3)	-	(3)
External sales	471	354	-	3,770	-	-	115	75	586	4,199
RESULTS										
Segment results	(90)	(203)	(26)	(49)	(3,250)	(2,126)	(360)	(361)	(3,726)	(2,739)
Finance costs	-	-	-	-	(49)	(80)	-	-	(49)	(80)
	(90)	(203)	(26)	(49)	(3,299)	(2,206)	(360)	(361)	(3,775)	(2,819)
Taxation									-	-
Loss for the period									(3,775)	(2,819)
Loss attributable to										
- owners of the Company									(3,775)	(2,819)
- non-controlling interest									-	-
Loss for the period									(3,775)	(2,819)
Depreciation of plant and equipment	-	-	-	-	(3)	(8)	(17)	(26)	(20)	(34)
Loss on fair value of hybrid financial instruments	-	-	-	-	-	(4)	-	-	-	(4)
Loss arising from extinguishment of loan	-	-	-	-	(63)	-	-	-	(63)	-
Loss on discontinued healthcare business	-	-	-	-	-	-	(125)	-	(125)	-

4. Segmental and revenue information (cont'd)

4.1 Reportable segments (cont'd)

The segment analysis on the Group's assets and liabilities as at 30 September 2026 and 31 December 2025 are as follows:

	Continuing Operations						Discontinued Operations		Combined	
	Outsourced Services		Commodity Trading		Corporate		Healthcare			
	As at 30 September 2026 RM'000	As at 31 December 2025 RM'000	As at 30 September 2026 RM'000	As at 31 December 2025 RM'000	As at 30 September 2026 RM'000	As at 31 December 2025 RM'000	As at 30 September 2026 RM'000	As at 31 December 2025 RM'000	As at 30 September 2026 RM'000	As at 31 December 2025 RM'000
Assets										
Segment assets	281	357	3	-	30,542	296	-	193	30,826	846
Sub-Total	281	357	3	-	30,542	296	-	193	30,826	846
Unallocated assets									-	-
Consolidated total assets									30,826	846
Liabilities										
Segment liabilities	180	291	18	24	910	5,805	59	201	1,167	6,321
Sub-Total	180	291	18	24	910	5,805	59	201	1,167	6,321
Unallocated liabilities									-	4
Consolidated total liabilities									1,167	6,325

4.2 Disaggregation of revenue

The disaggregation of the Group's revenue for continuing operations, are as follows:

Group	3 months ended 30 September ("3Q")			9 months ended 30 September ("9M")		
	3Q2026 RM'000	3Q2025 RM'000	Change +/(-)%	9M2026 RM'000	9M2025 RM'000	Change +/(-)%
Continuing operations						
Point in time						
Rendering of permanent placement services	168	103	63.1	471	354	33.1
Agricultural commodity trading	-	-	-	-	3,770	n.m.
	168	103	63.1	471	4,124	(88.6)

4.3 Geographical segment

The following table shows the distribution of the Group's combined sales based on geographical location of customers.

Group	3 months ended 30 September ("3Q")		9 months ended 30 September ("9M")	
	3Q2026 RM'000	3Q2025 RM'000	9M2026 RM'000	9M2025 RM'000
Continuing operations				
Singapore	168	103	471	354
China	-	-	-	3,770
Total revenue	168	103	471	4,124

5. Loss before tax

Loss for the financial period from continuing operations is arrived after charging the following:

Group	3 months ended 30 September ("3Q")			9 months ended 30 September ("9M")		
	3Q2026 RM'000	3Q2025 RM'000	Change +/(-)%	9M2026 RM'000	9M2025 RM'000	Change +/(-)%
Interest expense	(3)	(25)	(88.0)	(49)	(80)	(38.8)
Depreciation of property, plant and equipment	-	(3)	n.m.	(3)	(8)	(62.5)
Loss arising from extinguishment of loan	(63)	-	n.m.	(63)	-	n.m.
Loss on fair value of hybrid financial instruments	-	-	-	-	(4)	n.m.

6. Discontinued operations

Results of the discontinued operations are as follow:

Group	3 months ended 30 September ("3Q")			9 months ended 30 September ("9M")		
	3Q2026 RM'000	3Q2025 RM'000	Change +/(-)%	9M2026 RM'000	9M2025 RM'000	Change +/(-)%
Discontinued operations						
Revenue	-	18	n.m.	115	75	53.3
Cost of sales	-	(20)	n.m.	(87)	(36)	>100.0
Gross (loss) / profit	-	(2)	n.m.	28	39	(28.2)
Administrative expenses	-	(125)	n.m.	(262)	(400)	(34.5)
Exchange loss	-	-	-	(1)	-	n.m.
Other operating expenses	-	-	-	(125)	-	n.m.
Loss before tax	-	(127)	n.m.	(360)	(361)	(0.3)
Income tax	-	-	-	-	-	-
Loss for the period from discontinued operations	-	(127)	n.m.	(360)	(361)	(0.3)

The disaggregation of the Group's revenue for discontinued operations, are as follows:

Group	3 months ended 30 September ("3Q")			9 months ended 30 September ("9M")		
	3Q2026 RM'000	3Q2025 RM'000	Change +/(-)%	9M2026 RM'000	9M2025 RM'000	Change +/(-)%
Discontinued operations						
Point in time						
Sale of related products	-	8	n.m.	5	27	(81.5)
Rendering of chiro & physio services	-	-	-	2	6	(66.7)
Over time						
Rendering of chiro & physio services	-	10	n.m.	108	42	>100.0
	-	18	n.m.	115	75	53.3

The following table shows the distribution of the Group's combined sales based on geographical location of customers.

Group	3 months ended 30 September ("3Q")		9 months ended 30 September ("9M")	
	3Q2026 RM'000	3Q2025 RM'000	9M2026 RM'000	9M2025 RM'000
Discontinued operations				
Malaysia	-	18	115	75
Total revenue	-	18	115	75

Loss for the financial period from discontinued operations is arrived after charging the following:

Group	3 months ended 30 September ("3Q")			9 months ended 30 September ("9M")		
	3Q2026 RM'000	3Q2025 RM'000	Change +/(-)%	9M2026 RM'000	9M2025 RM'000	Change +/(-)%
Depreciation of property, plant and equipment	-	(8)	n.m.	(17)	(26)	(34.6)
Loss on discontinued healthcare business	-	-	-	(125)	-	n.m.

7. Trade receivables

	Company		Group	
	As at 30 September 2026 RM'000 (Unaudited)	As at 31 December 2025 RM'000 (Audited)	As at 30 September 2026 RM'000 (Unaudited)	As at 31 December 2025 RM'000 (Audited)
Third parties	-	-	177	246
Provision for doubtful debts – trade	-	-	(85)	(85)
	-	-	92	161

The trade receivables are derived from the Outsourced Services segment.

The Group uses a practical expedient to recognise the ECL for trade receivables, which is to measure the loss allowance at an amount equal to lifetime ECL using an allowance matrix derived based on historical credit loss experience adjusted for current conditions and forecasts of future economic conditions. The Group uses a provision matrix to measure ECL for trade receivables. The ECL rates are based on the Group's historical loss experience of the customers, for the last 3 years prior to the reporting date for various customer groups that are assessed by geographical locations, product types and internal ratings, adjusted for forward looking factors specific to the debtors and the economic environment which could affect the ability of the debtors to settle the trade receivables. In considering the impact of the economic environment on the ECL rates, the Group assesses, for example, the gross domestic production growth rates of the countries (Singapore and Malaysia) and the growth rates of the major industries in which its customers operate. The Group adjusts the allowance matrix at each reporting date. Such estimation of the ECL rates may not be representative of the actual default in the future.

8. Other receivables and prepayments

	Company		Group	
	As at 30 September 2026 RM'000 (Unaudited)	As at 31 December 2025 RM'000 (Audited)	As at 30 September 2026 RM'000 (Unaudited)	As at 31 December 2025 RM'000 (Audited)
Deposits	21	-	181	187
Prepayments	109	42	141	60
Amount due from subsidiaries	1,098	-	-	-
	1,228	42	322	247

Deposits include a banker's guarantee amounting to RM158,000, which was provided as a security deposit to the Singapore Ministry of Manpower in compliance with regulatory requirements for obtaining and maintaining a valid recruitment license.

9. Plant and equipment

During 9M2026, the Group did not acquire any plant and equipment (9M2025: RM4,000). There were no disposals of plant and equipment for 9M2026 and 9M2025.

10. Investment in subsidiaries

	Company	
	As at 30 September 2026 RM'000 (Unaudited)	As at 31 December 2025 RM'000 (Audited)
Unquoted equity shares, at cost	1	1
Quasi loans to subsidiaries	37,578	37,557
Allowance for impairment loss	(35,298)	(35,298)
Exchange differences	(2,281)	(2,260)
	-	-

Quasi loans to subsidiaries were non-trade in nature, unsecured and interest-free. The settlement of the amounts was neither planned nor likely to occur in the foreseeable future. As at 30 September 2026 and 31 December 2025, unquoted equity shares, at cost and quasi loan to subsidiaries were fully impaired due to the subsidiaries' continued loss-making positions, which adversely affected the recoverability of the investments.

11. Other payables

	Company		Group	
	As at 30 September 2026 RM'000 (Unaudited)	As at 31 December 2025 RM'000 (Audited)	As at 30 September 2026 RM'000 (Unaudited)	As at 31 December 2025 RM'000 (Audited)
Amount owing to a subsidiary	39	53	-	-
Accruals	337	382	450	653
Other payables	166	630	369	920
	542	1,065	819	1,573

Accruals include (i) directors' remuneration and fees amounting to nil (FY2025: RM151,000); and (ii) accrued staff expenses amounting to RM35,000 (FY2025: RM204,000); and (iii) accrued unutilised staff leave amounting to approximately RM21,000 (FY2025: RM21,000). The remaining accrual balances mainly pertain to accrued operating expenses such as professional fees and corporate support services related expenses.

The amount owing to a subsidiary are interest free and repayable on demand.

12. Provision

	Group	
	As at 30 September 2026 RM'000 (Unaudited)	As at 31 December 2025 RM'000 (Audited)
Provision	52	57
	52	57

Provision pertains to recruitment replacement guarantee under permanent placement services.

13. Borrowings

In relation to the aggregate amount of the Group's borrowings and debt securities, the following are convertible loans outstanding at the end of the financial period reported on with comparative figures as at the end of the immediately preceding financial year.

	Group and Company	
	As at 30 September 2026 RM'000 (Unaudited)	As at 31 December 2025 RM'000 (Audited)
Compound instrument	296	292
Loan	-	905
Hybrid financial instruments	-	-
	296	1,197
Represented by:		
Current liabilities	296	1,197
Non-current liabilities	-	-
	296	1,197

(a) Compound instrument

	Group and Company	
	As at 30 September 2026 RM'000 (Unaudited)	As at 31 December 2025 RM'000 (Audited)
Beginning balance of the year	292	304
Currency translation difference	4	(12)
Carrying amount of interest-bearing liabilities	296	292

(b) Loan

	Group and Company	
	As at 30 September 2026 RM'000 (Unaudited)	As at 31 December 2025 RM'000 (Audited)
Amortised cost as at beginning of the year	905	940
Accreted interest	49	98
Principal paid	(946)	-
Interest paid	(71)	(98)
Loss arising from loan extinguishment	63	-
Currency translation difference	-	(35)
Carrying amount of interest-bearing liabilities	-	905

(c) Hybrid financial instruments

	Group and Company	
	As at 30 September 2026 RM'000 (Unaudited)	As at 31 December 2025 RM'000 (Audited)
Fair value as at beginning of the year	-	324
Conversion into ordinary shares of the Company	-	(331)
Fair value adjustment of convertible loans	-	4
Currency translation difference	-	3
	-	-

Note: Hybrid financial instruments include accrued interests and recorded at fair value of the liability component. The fair value of the liability component is calculated using a market interest rate for an equivalent non-convertible loan at the date of issue. The residual amount, representing the value of the equity conversion component, is included in shareholders' equity in capital reserves.

Details of Borrowings as at 30 September 2026

(a) January 2021 convertible loan agreements

On 29 January 2021, the Company had entered into 1-year unsecured convertible loan agreements with 5 lenders, for an aggregate principal amount of S$2.25 million ("**29 Jan 2021 CLAs**"). The maturity date is 12 months from the date of disbursement of the loan. The convertible loan bears an interest rate of 10.0% per annum. At the option of the lenders, these loans are convertible into 56,532,663 ordinary shares in the Company at the conversion price of S$0.0398 per ordinary share on 3 specified dates (i.e. 30 June 2021, 30 September 2021 and/or 31 December 2021). Please refer to the Company's announcement dated 29 January 2021, 4 February 2021, 1 April 2021 and 12 April 2021 for more information.

Of the S$2.25 million, a principal sum of S$1.6 million was converted by I Concept Global Growth Fund into 40,201,005 new ordinary shares of the Company at S$0.0398 per ordinary share. Please refer to the Company's announcement dated 31 December 2021 for more information. S$0.45 million principal of the 29 January 2021 CLAs has been fully repaid. On 7 November 2022, the Company entered into supplemental agreements with each Wong Soh Shyan and Wong Chui Chui, who were lenders of the 29 January 2021 CLAs, to extend the maturity date of amounts totalling S$200,000 till 31 October 2025. More details can be found in the Company's announcement dated 8 November 2022. The remaining balance principal of S$200,000 was fully repaid in July 2026.

(b) March 2023 loan agreement

On 1 March 2023, Wong Soh Shyan extended a loan of S$100,000 (approximately RM332,000) to the Company. The loan has a 10% interest per annum and shall be repayable within 3 years from the date of the drawdown. This loan was fully repaid in July 2026.

14. **Amounts due to shareholders**

	Group and Company	
	As at 30 September 2026 RM'000 (Unaudited)	As at 31 December 2025 RM'000 (Audited)
Loan	-	3,232
Payment on behalf	-	201
	-	3,433

As at 30 June 2026, the non-interest bearing loans totalling S$1,504,000 (approximately RM4.7 million) from Mr Chua. Of the total amount, S$947,696 (approximately RM3.0 million) were converted into 47,384,782 ordinary shares of the Company pursuant to the Rights Issue completed on 6 July 2026, while the remaining S$556,304 (approximately RM1.7 million) was repaid in full on 10 July 2026 and 16 September 2026. Accordingly, there was no more outstanding loan due to Mr Chua as at 30 September 2026. Payment on behalf consists of settlement for marketing expenses by Mr Chua which was fully repaid on 16 September 2026.

Amounts due to shareholders are denominated in Singapore dollar.

15. Financial assets and financial liabilities

Set out below is an overview of the financial assets and financial liabilities of the Group as at 30 September 2026 and 31 December 2025:

	Company		Group	
	As at 30 September 2026 RM'000 (Unaudited)	As at 31 December 2025 RM'000 (Audited)	As at 30 September 2026 RM'000 (Unaudited)	As at 31 December 2025 RM'000 (Audited)
Financial Assets				
Financial assets at amortised cost	31,506	156	30,685	609
Financial Liabilities				
Financial liabilities at amortised cost	838	5,695	1,115	6,203

Financial assets consist of cash and bank balances, trade and other receivables, excluding prepayments. Financial liabilities consist of other payables, borrowings and amounts due to shareholders.

16. Subsequent events

Nil.

F. OTHER INFORMATION REQUIRED BY CATALIST RULE APPENDIX 7C

1. Details of any changes in the company's share capital arising from rights issue, bonus issue, subdivision, consolidation, share buy-backs, exercise of share options or warrants, conversion of other issues of equity securities, issue of shares for cash or as consideration for acquisition or for any other purpose since the end of the previous period reported on. State the number of shares that may be issued on conversion of all the outstanding convertibles, if any, against the total number of issued shares excluding treasury shares and subsidiary holdings of the issuer, as at the end of the current financial period reported on and as at the end of the corresponding period of the immediately preceding financial year. State also the number of shares held as treasury shares and the number of subsidiary holdings, if any, and the percentage of the aggregate number of treasury shares and subsidiary holdings held against the total number of shares outstanding in a class that is listed as at the end of the current financial period reported on and as at the end of the corresponding period of the immediately preceding financial year.

	Number of shares	Resultant issued and paid-up share capital (S$)
Issued and paid-up share capital of the Company as at 31 December 2025 (excluding treasury shares)	378,102,012	55,847,495
Issuance of new ordinary shares	367,639,006	12,531,832
Issued and paid-up share capital of the Company as at 30 September 2026 (excluding treasury shares)	745,741,018	68,379,327

On 17 February 2025, the Company announced the allotment and issuance of 2,096,436 new Shares in the capital of the Company pursuant to the terms for the conversion of non-redeemable convertible loan notes with an aggregate principal of S$100,000. Further details are available in the Company's announcements dated 17 February 2025.

On 22 December 2025, the Company announced the completion of the proposed conversion of the Outstanding Debt owed by the Company to the Lender into 213,965,134 new ordinary shares in the capital of the Company at the conversion price of S$0.015 for each Debt Conversion Share. Further details are available in the Company's Circular dated 28 November 2025 and announcement dated 22 December 2025.

On 6 July 2026, the Company announced the completion of the proposed renounceable non-underwritten rights issue of 189,051,006 new ordinary shares in the capital of the Company at an issue price of S$0.02 for each Rights Share, on the basis of one (1) Rights Share for every two (2) existing Shares held by eligible shareholders as at the record date. Further details are available in the Company's announcements dated 11 May 2026, 15 May 2026, 20 May 2026, 29 May 2026, 4 June 2026, 11 June 2026, 15 June 2026, 2 July 2026 and 6 July 2026.

On 25 August 2026, the Company announced the completion of the proposed shares placement of 178,588,000 new ordinary shares in the capital of the Company to the respective subscribers at the placement price of S$0.049 for each Placement Share. Further details are available in the Company's announcements dated 18 August 2026, 20 August 2026 and 25 August 2026.

Save as disclosed above and under Section E Paragraph 13, there were no outstanding convertibles, share options or subsidiary holdings as at 30 September 2026 and 31 December 2025.

The total number of treasury shares as at 30 September 2026 and 31 December 2025 are presented below:

	As at 30 September 2026	As at 31 December 2025
Total number of treasury shares	20,000	20,000
Total number of ordinary shares	745,741,018	378,102,012
% of treasury shares over total number of ordinary shares	0.003%	0.005%

2. To show the total number of issued shares excluding treasury shares at the end of the current financial period and as at the end of the immediately preceding financial year

	As at 30 September 2026	As at 31 December 2025
Number of issued shares of the Company	745,761,018	378,122,012
Share buy-backs held as treasury shares	(20,000)	(20,000)
Number of issued shares excluding treasury shares	745,741,018	378,102,012

3. A statement showing all sales, transfers, disposal, cancellation and / or use of treasury shares as at the end of the current financial period reported on.

There were no sales, transfers, disposal, cancellation and /or use of treasury shares as at 30 September 2026.

4. A statement showing all sales, transfers, cancellation and / or use of subsidiary holdings as at the end of the current financial period reported on.

There were no sales, transfers, cancellation and / or use of subsidiary holdings as at 30 September 2026.

5. Where the latest financial statements are subject to an adverse opinion, qualified opinion or disclaimer of opinion:

a) Updates on the efforts taken to resolve each outstanding audit issue.

b) Confirmation from the Board that the impact of all outstanding audit issues on the financial statements have been adequately disclosed.

This is not required for any audit issue that is a material uncertainty relating to going concern.

Please refer to Section E Paragraph 2.4 for the Board's comments on going concern.

Further the Board is of the opinion that sufficient information has been disclosed for the trading of the Company's securities to continue in an orderly manner and the Board is not aware of any material information that requires disclosure but remains undisclosed as of the date of this announcement.

6. Loss per ordinary share of the group for the current period reported on and the corresponding period of the immediately preceding financial year, after deducting any provision for preference dividends

Group	3Q2026 (Malaysia sen)	3Q2025 (Malaysia sen)	9M2026 (Malaysia sen)	9M2025 (Malaysia sen)
Loss per ordinary share for the period based on the net loss attributable to shareholders of the Company:				
(i) Basic				
- from continuing operations	(0.28)	(0.57)	(0.66)	(1.50)
- from discontinued operations	-	(0.08)	(0.07)	(0.22)
	(0.28)	(0.65)	(0.73)	(1.72)
(ii) On a fully diluted basis	(0.28)	(0.65)	(0.73)	(1.72)
Weighted average number of ordinary shares	633,268,391	164,136,878	519,799,485	163,775,953

Basic and diluted loss per ordinary share have been computed based on the Group's loss attributable to owners of the Company and the weighted average number of ordinary shares in issue during the respective periods.

The basic and fully diluted loss per ordinary share for 3Q2026 and 3Q2025, 9M2026 and 9M2025 were the same as there were no potentially dilutive ordinary shares existing during 3Q2026 and 3Q2025, 9M2026 and 9M2025 respectively.

7. Net asset value (for the issuer and group) per ordinary share based on issued share capital of the issuer at the end of the (a) current period reported on and (b) immediately preceding financial year

	Net asset value per ordinary share (Malaysian sen)	
	As at 30 September 2026	As at 31 December 2025
Group	4.0	(1.4)
Company	4.1	(1.5)

Net asset value per ordinary share as at 30 September 2026 and 31 December 2025 have been calculated based on the aggregate number of ordinary shares of 745,741,018 and 378,102,012 as at the respective dates, excluding treasury shares.

8. A review of the performance of the group, to the extent necessary for a reasonable understanding of the group's business. The review must discuss any significant factors that affected the turnover, and earnings of the group for the current financial period reported on, including (where applicable) seasonal or cyclical factors. It must also discuss any material factors that affected the cash flow, working capital, assets or liabilities of the group during the current financial period reported on

Review of Statement of Comprehensive Income

Continuing Operations

Breakdown by business segments

Three Months ended 30 September 2026 and 30 September 2025

Business segment	3Q2026			3Q2025		
	Revenue (RM'000)	Gross Profit (RM'000)	GP Margin %	Revenue (RM'000)	Gross Loss (RM'000)	GP Margin %
Continuing Operations						
Outsourced services	168	12	7.1	103	(59)	(57.3)
Commodity trading	-	-	-	-	-	-
Total	**168**	**12**	**7.1**	**103**	**(59)**	**(57.3)**

Nine Months ended 30 September 2026 and 30 September 2025

Business segment	9M2026			9M2025		
	Revenue (RM'000)	Gross Profit (RM'000)	GP Margin %	Revenue (RM'000)	Gross Profit/(Loss) (RM'000)	GP Margin %
Continuing Operations						
Outsourced services	471	13	2.8	354	(130)	(36.7)
Commodity trading	-	-	-	3,770	49	1.3
Total	**471**	**13**	**2.8**	**4,124**	**(81)**	**(2.0)**

Revenue

Revenue for the Group increased by RM65 thousand or approximately 63.1% from RM103 thousand in 3Q2025 to RM168 thousand in 3Q2026. The increase was due mainly to increased job placements by the outsourced services. There was no commodity trading activity in 3Q2026 as a result of market conditions offered high volatility in pricing of commodities such as coffee beans, cocoa, etc. Severe geopolitical disruptions and extreme weather patterns drove the massive price volatility.

Revenue for the Group in 9M2026 decreased by RM3.6 million or approximately 88.6% from RM4.1 million in 9M2025 to RM0.5 million in 9M2026 due mainly to no commodity trading activity in 9M2026. The decrease was partially offset by an increase of RM117 thousand in revenue from outsourced services from RM354 thousand in 9M2025 to RM471 thousand in 9M2026.

Gross Profit/(Loss)

For 3Q2026, the Group recorded a gross profit of RM12 thousand compared to the gross loss of RM59 thousand in 3Q2025, mainly due to the higher direct costs incurred by the outsourced services segment in 3Q2025. The increase corresponded with the increase in revenue for the same comparative period.

The Group recorded a gross profit of RM13 thousand in 9M2026 compared to the gross loss of RM81 thousand in 9M2025 due mainly to the gross loss from the outsourced services segment in 9M2025 as a result of higher direct costs incurred which was partially offset by the gross profit from the commodity trading segment in the same period.

Other Operating Income

The other operating income in 9M2026 increased by RM22 thousand or approximately 314.3% from RM7 thousand in 9M2025 to RM29 thousand in 9M2026, due mainly to a reversal of accrued professional fee of RM19 thousand previously recognised for a project that is no longer ongoing and a one-off Corporate Income Tax cash grant received from the Inland Revenue Authority of Singapore of RM10 thousand. In comparison, the Group reported other operating income of RM7 thousand for 9M2025 was due mainly to government incentives and subsidies.

Administrative Expenses

Administrative expenses in 3Q2026 increased by RM0.6 million or approximately 79.6% from RM0.9 million in 3Q2025 to RM1.5 million in 3Q2026. The increase was due mainly to the corporate and legal costs incurred for the Rights Issue and Shares Placement completed on 6 July 2026 and 25 August 2026 respectively.

The administrative expenses in 9M2026 increased by RM1.0 million or approximately 42.8% from RM2.2 million in 9M2025 to RM3.2 million in 9M2026. The increase was due mainly to the corporate and legal costs incurred for the Rights Issue and Shares Placement completed on 6 July 2026 and 25 August 2026 respectively, and the printing costs for compliance reporting for year 2025 and 2026.

Exchange Gain/Loss

The Group recorded an exchange loss of RM172 thousand in 3Q2026 compared to an exchange loss of RM6 thousand in 3Q2025. The exchange loss for 3Q2026 was due mainly to the further weakening of the Malaysia Ringgit against the Singapore Dollar in 3Q2026 since June 2026 whilst translating the intercompany loans denominated in Singapore Dollar.

For 9M2026, the Group recorded an exchange loss of RM139 thousand compared to an exchange loss of RM55 thousand for 9M2025. The exchange loss for 9M2026 was due mainly to the further weakening of the Malaysia Ringgit against the Singapore Dollar in 9M2026 thereby increase the cost of payables and loans that are denominated in Singapore Dollar.

Other Operating Expenses

Other operating expenses in 3Q2026 increased by RM63 or approximately 100.0% from nil in 3Q2025 due to loss arising from loan extinguishment of the S$200 thousand convertible loan notes due to both Wong Soh Shyan and Wong Chui Chui in aggregate and a S$100 thousand loan due to Wong Soh Shyan which were both fully repaid on 7 July 2026.

The other operating expenses in 9M2026 increased by RM59 thousand or approximately 1,475.0 % from RM4 thousand in 9M2025 due mainly to fair value adjustment upon the conversion of convertible loan notes with an aggregate principal of S$100 thousand into new ordinary shares in the Company in February 2025 and loss arising from loan extinguishment of the S$200 thousand convertible loan notes and S$100 thousand loan which were fully repaid on 7 July 2026.

Finance Costs

Finance costs for 3Q2026 decreased by RM22 thousand, approximately 88.0% from RM25 thousand in 3Q2025 to RM3 thousand in 3Q2026. The decrease was due mainly to the settlement of convertible loan notes with an aggregate principal of S$200 thousand and a loan with an aggregate principal of S$100 thousand on 7 July 2026.

The finance costs in 9M2026 decreased by RM31 thousand, approximately 38.8% from RM80 thousand in 9M2025 to RM49 thousand in 9M2026. The decrease was due mainly to the same reason as above.

Loss Before Tax

For the reasons set out above, the Group recorded a loss before tax of RM1.7 million for 3Q2026 as compared to a loss before tax of RM0.9 million for 3Q2025. For 9M2026, the Group recorded a loss before tax of RM3.4 million as compared to a loss before tax of RM2.5 million for 9M2025.

Discontinued Operations

Revenue

For 3Q2026, revenue from the discontinued "Healthcare Services" decreased RM18 thousand or approximately 100.0% from RM18 thousand in 3Q2025 to nil in 3Q2026. The decrease was due mainly to the cessation of the Healthcare Services as at 30 September 2026. Revenue for 9M2026 increased by RM40 thousand approximately 53.3% from RM75 thousand in 9M2025 to RM115 thousand in 9M2026 as more patients visited the centre.

Gross Profit/(Loss)

For 3Q2026, the Group recorded a gross loss of nil compared to the gross loss of RM2 thousand in 3Q2025, a decrease of gross loss of RM2 thousand was due mainly to cessation of the Healthcare Services as at 30 September 2026.

The Group recorded a gross profit of RM28 thousand in 9M2026 compared to the gross profit of RM39 thousand in 9M2025, a decrease of gross profit of RM11 thousand was due mainly to the usage of more locum therapist services compared to hiring inhouse chiropractic and physio therapists to treat the patients in 9M2026 to cover staff gap, which was more costly.

Administrative Expenses

Administrative expenses in 3Q2026 decreased by RM125 thousand or approximately 100.0% from RM125 thousand in 3Q2025 to nil in 3Q2026. The decrease was due mainly to complete cessation of operational costs in 3Q2026 as the Healthcare Services segment ceased as at 30 September 2026.

The administrative expenses in 9M2026 decreased by RM138 thousand or approximately 34.5% from RM400 thousand in 9M2025 to RM262 thousand in 9M2026. The decrease was due mainly to the same reason as above.

Other Operating Expenses

Other operating expenses for 3Q2025 and 9M2025 were nil. Other operating expenses for 3Q2026 was nil and 9M2026 was RM125 thousand. These expenses were due mainly to loss on disposal of inventories of RM115 thousand and loss on disposal of plant and equipment of RM33 thousand, which was offset by gain on transfer of contract liabilities of RM23 thousand of the discontinued operations of the Healthcare Services segment.

Loss Before Tax

For the reasons set out above, the Group recorded a loss before tax of nil for 3Q2026 as compared to a loss before tax of RM127 thousand for 3Q2025 for the discontinued operations. For 9M2026, the Group recorded a loss before tax of RM360 thousand as compared to a loss before tax of RM361 thousand for 9M2025 for the discontinued operations

Review of Statement of Financial Position

Current Assets

The Group's cash and bank balances increased to RM30.4 million as at 30 September 2026 from RM0.3 million as at 31 December 2025 due mainly to the gross proceeds of RM10.4 million (S$3.6 million) and RM27.8 million (S$8.6 million) from Rights Issue and Shares Placement completed on 6 July 2026 and 25 August 2026 respectively. The Group's trade receivables decreased to RM92 thousand as at 30 September 2026 from RM161 thousand as at 31 December 2025 due mainly to settlement of trade receivables from the Outsource Services segment. The Group's other receivables and prepayments increased to RM322 thousand as at 30 September 2026 from RM247 thousand as at 31 December 2025 due mainly to prepaid office rent and expense payments. Inventories were nil as at 30 September 2026 and RM124 thousand as at 31 December 2025 as they were disposed off following the discontinuation of the Healthcare services.

Non-Current Assets

The Group's plant and equipment decreased to nil as at 30 September 2026 from RM53 thousand as at 31 December 2025 were due mainly to depreciation charges of RM20 thousand for 9M2026 and the plant and equipment from the discontinued Healthcare Services were disposed and excluded from the Statement of Financial Position.

Capital and Reserves

Share capital of the Company and the Group increased to RM186.0 million as at 30 September 2026 from RM147.4 million as at 31 December 2025. The increase was due to the issue of 367,639,006 new ordinary shares pursuant to the Rights Issue and Shares Placement exercises completed on 6 July 2026 and 25 August 2026 respectively. The Group's currency translation reserve was a gain of RM190 thousand as at 30 September 2026 compared to a deficit of RM56 thousand as at 31 December 2025 due mainly to the weakening of the Malaysia Ringgit against the Singapore Dollar in 9M2026. Capital reserves remained unchanged at RM3.9 million as at 30 September 2026 and 31 December 2025. Accumulated losses for the Group increased by RM3.7 million to RM160.4 million as at 30 September 2026 from RM156.7 million as at 31 December 2025 due to the losses recorded for 9M2026.

Non-Current Liabilities and Current Liabilities

Other payables for the Group as at 30 September 2026 decreased by RM0.8 million to RM0.8 million as at 30 September 2026 from RM1.6 million as at 31 December 2025 due mainly to: (i) payment of RM0.4 million for accrued manpower expenses, and director remuneration and fees, (ii) RM0.1 million increase in accruals and payables for corporate and professional services, and (iii) refund of unsuccessful excess Rights Issue application monies received from 4 substantial shareholders amounting to RM0.5 million during June 2026.

Provisions decreased from RM57 thousand as at 31 December 2025 to RM52 thousand as at 30 September 2026. This movement reflects the reversal of provisions amounting to RM16 thousand in 3Q2026, following the expiry of guarantee periods for earlier recruitment contracts, which was recognised as revenue during the period. In addition, new provisions were recognised for ongoing recruitment contracts with unexpired guarantee periods, resulting in a closing balance of RM52 thousand as at 30 September 2026.

Borrowings decreased to RM0.3 million as at 30 September 2026 from RM1.2 million as at 31 December 2025 due to full settlement of RM0.9 million convertible note loans and loans owing to Wong Soh Shyan and Wong Chui Chui. Contract liabilities decreased to nil as at 30 September 2026 from RM61 thousand as at 31 December 2025 due to contract liabilities of the discontinued Healthcare Services that was excluded from the Statement of Financial Position. Amount due to shareholders decreased by RM3.4 million to nil as at 30 September 2026 from RM3.4 million as at 31 December 2025 due mainly to set-off of subscription amount of RM3.0 million (S$1.0 million) payable by Mr Chua for his Rights shares against part of the Total Debt owing by the Company to him under the deed of set-off entered into between the Company and Mr. Chua on 4 June 2026 as disclosed in the Offer Information Statement (Rights Issue exercise completed on 6 July 2026), and the full settlement of balance loans and payment on behalf of marketing expenses due to Mr Chua. The Rights Issue application and allotment monies of RM3.8 million paid by 4 substantial shareholders received in 2Q2026 were converted into ordinary shares when the Rights Issue exercise completed on 6 July 2026.

Review of Statement of Cash Flows

For 3Q2026, the Group used RM3.7 million in operating activities, due mainly to RM1.7 million operating loss before working capital changes, an increase in trade and other receivables and prepayments of RM35 thousand and a decrease in trade and other payables of RM2.0 million, which were offset by a RM63 thousand loss arising from extinguishment of loans. There were no investing activities in 3Q2026. Net cash generated from financing activities in 3Q2026 of RM28.9 million was due to gross proceeds of RM10.4 million (S$3.6 million) and RM27.8 million (S$8.59 million) from Rights Issue and Shares Placement completed on 6 July 2026 and 25 August 2026 respectively, offset by (i) the return of RM1.0 million convertible note loans and loans owing to Wong Soh Shyan and Wong Chui Chui, (ii) repayment of advances of RM3.8 million paid by 4 substantial shareholders by converting the Rights Issue application and allotment monies into ordinary shares of the Company (iii) Repayment part of the Total Debt owing by the Company owing to Mr. Chua by setting-off the subscription amount of RM3.0 million (S$1.0 million) payable by him for his Rights shares, and (iv) return of RM1.9 million of loans and payment on behalf of marketing expenses to the substantial shareholder Mr. Chua.

For 9M2026, the Group used RM4.5 million in operating activities, due mainly to RM3.5 million operating loss before working capital changes and RM125 thousand loss on discontinued Healthcare business which was offset by a RM0.9 million increase in trade and other payables and other provisions. There were no investing activities in 9M2026. Net cash generated from financing activities in 9M2026 of RM34.1 million was due mainly to same reasons for 3Q2026.

9. Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results

No forecast or prospect statement has been previously disclosed to shareholders.

10. A commentary at the date of the announcement of the significant trend competitive conditions of the industry in which the group operates and any known factors or events that may affect the group in the next reporting period and the next 12 months

The Group continues to navigate persistent macroeconomic uncertainties and the rapid acceleration of technology in service sectors, our strategic focus is on its continuing operations. Over the coming year, the competitive landscape will largely be dictated by fluctuations in commodity markets driven by weather, unstable crude oil prices and regulatory changes, and a fundamental shift in the recruitment sector as artificial intelligence becomes deeply integrated into talent sourcing and candidate screening processes.

A. COMMODITY TRADING BUSINESS OVERVIEW

Coffee Trading

2026 outlook projects that global coffee production will climb 2.5% year-over-year to 170 million bags for the 2025/26 market year[1]. This critical supply-side forecast reflects improved crop yields and sustained agricultural investments driven by historically high robusta export prices that will see Robusta beans production growing faster than Arabica beans thereby growing its share in the bulk segment. These metrics serve as practical determinants that will directly dictate trading conditions over the next 12 months by influencing physical availability, origin differentials, and global price volatility.

For 2027 outlook, global coffee production will surge to a record 189 million bags, creating a heavy global surplus for the 2026/27 year. Arabica beans output will lead the charge while robusta output will tighten due to Brazilian Robusta (Conilon) trees are entering an off-year recovery cycle. Prices will be facing strong bearish pressure due to the projected global market surplus. Additionally, the geographic focus pivot to Brazil due to hot zones like Indonesia and Vietnam faces severe climate stress heading into 2027[2].

As these supply and pricing signals continue to evolve, robust trading performance will be fundamentally driven by disciplined risk controls and rigorous counterparty selection. Maintaining margins will rely heavily on the operational agility to respond rapidly to origin-specific developments, particularly Vietnam and Indonesia's immediate supply trajectory, shifting export dynamics and strict laws and regulations compliance.

[1] Coffee market in 2026 - market dynamics, analysis | Global Report | Foodcom S.A.

[2] United States Department of Agriculture Foreign Agricultural Service - Coffee: World Markets and Trade

Palm Acid Oil (PAO)

Driven by Middle Eastern conflicts that disrupted global oil supplies and aggressively narrowed the palm oil-gasoil (Pogo) price spread, President Prabowo Subianto officially reinstated the B50 target[3]. The mandate took effect on July 1, 2026, with the aim to achieve total energy independence and entirely halt low-grade diesel imports.

The Indonesian Ministry of Energy and Mineral Resources (ESDM) has confirmed that Indonesia will continue its mandatory B50 biodiesel program into 2027, while actively preparing to escalate to a B60 blend. The full B60 blend transition may stretch out over two to three years due to capacity shortage in plant expansions[4].

Indonesia's domestic palm oil absorption will remain highly elevated through 2027. The elevated domestic demand, combined with lagging crop yields from the late-2026 EL Nino weather cycle, is highly likely to tighten global CPO export supplies and drive up regional palm oil prices in 2027[5].

The global palm oil market is experiencing a significant structural squeeze heading into 2027. Driven by and unprecedented combination of aggressive domestic biofuel mandates of Indonesia's B50 mandate and Malaysia's B15 mandate and an intense lagging El Nino weather cycle, the supply-demand balance for palm and key feedstocks including PAO is tightening[6].

This structural deficit is shifting the pricing dynamics, positioning palm oil to potentially reclaim a price premium over competing vegetable oils like soyabean oil by early 2027.

B. OUTSOURCED SERVICES BUSINESS OVERVIEW

The recruitment sector remains highly competitive, with differentiation fundamentally driven by process speed, match quality, and technology-enabled efficiency. Artificial intelligence (AI) has rapidly transitioned from a niche capability to a mandatory mainstream requirement; with 84% of organizations globally planning in 2026 to utilise AI technology within their hiring processes[7].

Competitive pressure has decisively shifted toward recruitment agencies that can effectively embed automation into their sourcing, screening, and communication workflows. Agencies are rapidly integrating artificial intelligence into their daily operations to automate repetitive tasks, shrink hiring timelines, and handle high-volume candidate interactions. Agencies leveraging these advanced tools report profound operational gains with 30%-50% in cost savings and 33% reduction in time-to-hire with AI tools[8].

Singapore hiring and workforce trends for 2027 are defined by cautious optimism, selective recruitment, and a strong focus on AI and adaptability. According to Singapore National Employer Federation (SNEF), more than half of small and medium sized employers do not intend to increase headcount in 2027. A majority also plan to freeze or moderate wages, despite a slight improvement in their business outlook for the year. More companies also reported worries over the rising cost of upskilling and reskilling their workers as they prepare for evolving business and technology[9].

In this saturated operating context and hiring demand and rising manpower cost challenges, the Group's focus on AI-enabled process improvements is an essential structural response. Moving forward, sustaining a competitive advantage will require maximizing high-speed automated execution while actively mitigating algorithmic bias which requires regular monitoring[8].

C. GENERAL

There are other business opportunities that the Group is currently exploring and evaluating. The Group will make announcement(s) at an appropriate time as and when the commercial terms of each or any of these business opportunities are finalised.

[3] Indonesia targets 50pc biodiesel blend in 2026 | Latest Market News
[4] Indonesia assesses CPO supply for B60 biodiesel rollout in 2027
[5] Palm oil set to reclaim premium over soyoil in 2027 on supply risks
[6] Palm oil's 2027 squeeze: B50, El Nino and stocks expected to gain the most
[7] Korn Ferry. (March 12, 2026). *"TA Trends 2026: Human–AI Power Couple | Full Report."* Details the 84% adoption rate and the strategic transition toward autonomous "Agentic AI."
[8] AI-Powered Recruitment Singapore 2026: Implementation Guide | Mavenside Consulting
[9] Over half of employers plan hiring freeze, wage moderation despite better outlook: SNEFpoll

11. If a decision regarding dividend has been made:

(a) Whether an interim (final) ordinary dividend has been declared (recommended)

No.

(b) Previous corresponding period/rate %

None.

12. If no dividend has been declared (recommended), a statement to that effect

There is no interim dividend recommended and declared by the Directors in respect of the current financial period ended 30 September 2026 as the Group recorded a loss in 9M2026.

13. Related party transactions and Interested Party Transaction ("IPT"). If the Group has obtained a general mandate from shareholders for IPTs, the aggregate value of such transactions as required under Rule 920(1)(a)(ii). If no IPT mandate has been obtained, a statement to that effect

Save for remuneration of directors and other members of key management during the financial period, there were no other related party transactions.

The Group does not have a general mandate from shareholders for interested person transactions ("**IPTs**") pursuant to Rule 920(1)(a)(ii) of the Listing Manual Section B: Rules of Catalist of the Singapore Exchange Securities Trading Limited (the "**Catalist Rules**"). Other than the payment of behalf of RM4.9 million owing by the Group to Mr Chua, there were no IPTs entered into during the financial period reported on which exceeds S$100,000 in value.

14. Use of Proceeds

Rights Issue

On 6 July 2026, the Group completed the Rights Issue and raised net proceeds of approximately S$3.6 million ("**Net Proceeds**"). Please refer to the Company's offer information statement dated 11 June 2026 ("**Offer Information Statement**") for more information.

The status of the use of the Net Proceeds from the Rights Issue as at the date of this announcement is as follows:

Use of Net Proceeds	Amount of Net Proceeds (S$'000)	Amount utilised as at the date of this announcement (S$'000)	Balance as at the date of this announcement (S$'000)
Shareholder Loan Set-off	948	(948)[(1)]	-
General working capital which includes, among others, administrative expenses, manpower costs, compliance costs, continuing listing expenses, professional fees and general overheads	2,040	(1,089)[(2)]	951
Repayment of borrowings of the Company	323	(323)[(3)]	-
Business development, strategic investments and/or acquisitions and expansion opportunities	250	-	250
Total	**3,561**	**(2,360)**	**1,201**

Notes:

(1) Relates to the set-off arrangement under the deed of set-off entered into between the Company and Mr. Chua on 4 June 2026, pursuant to which the subscription amount of S$947,695.64 payable by Mr. Chua for his Undertaken Rights Shares under his Irrevocable Undertaking will be satisfied by way of set-off against part of the Total Debt owing by the Company to him, as disclosed in the Offer Information Statement.

(2) A breakdown of the use of Net Proceeds paid for general working capital purposes of the Company is as follows:

	S$'000
Manpower costs	420
Compliance costs	163
Continuing listing expenses	188
Professional fees	219
General overheads	99
	1,089

(3) Relates to repayment of borrowings (including loan principal and interests) to non-related parties.

The use of net proceeds disclosed above is in accordance with the intended uses as disclosed in the Rights Issue Offer Information Statement. The Company will continue to make periodic announcements via SGXNet on the utilisation of the balance of the IPO net proceeds as and when such proceeds are materially disbursed.

Shares Placement

On 25 August 2026, the Group completed the Shares Placement and raised net proceeds of approximately S$8.6 million ("**Net Proceeds**"). Please refer to the Company's announcement on 17 August 2026 for more information.

The status of the use of the Net Proceeds from the Shares Placement as at the date of this announcement is as follows:

Use of Net Proceeds	Amount of Net Proceeds (S$'000)	Amount utilised as at the date of this announcement (S$'000)	Balance as at the date of this announcement (S$'000)
Repayment of shareholder's loan	456	(456)	-
General working capital which includes, among others, administrative expenses, manpower costs, compliance costs, continuing listing expenses, professional fees and general overheads	2,120	(306)	1,814
Business development and expansion opportunities, including but not limited to new project financing, strategic investments, mergers and acquisitions, strategic partnerships	6,013	-	6,013
Total	**8,589**	**(762)**	**7,827**

Notes:

(1) A breakdown of the use of Net Proceeds paid for general working capital purposes of the Company is as follows:

	S$'000
Compliance costs	6
Continuing listing expenses	10
Professional fees	285
General overheads	5
	306

The use of net proceeds disclosed above are in accordance with the intended uses as disclosed in the announcement dated 17 August 2026. The Company will continue to make periodic announcements via SGXNet on the utilisation of the balance of the net proceeds as and when such proceeds are materially disbursed.

15. Confirmation by the Board of Directors pursuant to Rule 705(5) of the Catalist Rules

We, Tan Lee Seng and Alan Yong Thiam Fook, being Directors of the Company, do hereby confirm on behalf of the Board of Directors of the Company that, to the best of our knowledge, nothing has come to the attention of the Board of Directors of the Company which may render the unaudited financial statements for third quarter and nine months ended 30 September 2026 to be false or misleading in any material aspect.

16. Confirmation that the issuer has procured undertakings from all its directors and executive officers (in the format set out in Appendix 7H) under Rule 720(1) of the Catalist Rules.

The Company confirms that all the required undertakings under the Rule 720(1) of the Catalist Rules have been obtained from its Directors and Executive Officers in the format set out in Appendix 7H of the Catalist Rules.

17. Disclosure on Acquisitions and Realisation of Shares pursuant to Catalist Rule 706(A)

In its continuing strategy to rationalise the Group structure, the Group had in October 2025 commenced the application process for striking-off of a wholly owned dormant subsidiary, Healthpro Life Sdn. Bhd. ("**HPL**"). None of the Directors and substantial shareholders of the Company has any interest, direct or indirect, in the strike-off, save for their shareholdings in the Company (if any). In January 2026, HPL was gazetted for strike off under Section 551(3) of the Companies Act 2016 and is pending final tax clearance from the local tax authorities. Final tax clearance has been obtained from the local tax authorities on 19 August 2026.

As at 30 September 2026, the Group's wholly owned subsidiaries, Back to Life Sdn Bhd and Healthpro Marketing Sdn Bhd, remained inactive following the discontinuation of their operations on 30 June 2026. This forms part of the Group's restructuring and consolidation of operations and is not expected to have any material impact on the net tangible assets and earnings per share of the Group for the financial year ended 31 December 2026. None of the directors or substantial shareholders of the Company have any interest, direct or indirect, in the discontinued operations, save for their shareholdings (if any) in the Company.

Save as disclosed above, there were no acquisition or realisation of shares in any of the Group's subsidiary or associated company nor incorporation of any new subsidiary or associated company by the Company or any of the Group's entities during the third quarter and nine months ended 30 September 2026.

ON BEHALF OF THE BOARD OF DIRECTORS

TAN LEE SENG EXECUTIVE DIRECTOR & CEO	ALAN YONG THIAM FOOK NON-INDEPENDENT NON-EXECUTIVE CHAIRMAN

Date: 13 November 2026

---

*This announcement has been reviewed by the Company's Sponsor, SAC Capital Private Limited (the "**Sponsor**") . This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited ("**SGX-ST**") and SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made, or reports contained in this announcement.*

The contact person for the Sponsor is Ms. Lee Khai Yinn, at 1 Robinson Road, #21-01 AIA Tower, Singapore 048542, telephone (65) 6232 3210.
